KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch.

Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu

World J Gastroenterol 31(26) 109285

PMID40678712
PMCIDPMC12264858
DOI10.3748/wjg.v31.i26.109285
发表日期2025-07-18
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Tenofovir amibufenamide (TMF) has shown antiviral efficacy comparable to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB), with improved renal and bone safety profiles. While TDF is recognized for its lipid-lowering properties, the long-term effects of TMF on lipid metabolism remain unclear. AIM: To assess lipid changes and long-term safety of TMF in CHB, including outcomes after TDF-to-TMF switch over 144 weeks. METHODS: This retrospective analysis utilized data from a phase III randomized, double-blind trial involving 53 patients with CHB treated with either TMF 25 mg (n = 39) or TDF 300 mg (n = 14) once daily for 96 weeks. Following this blinded phase, all participants entered an open-label extension in which they received TMF until week 144. This design enabled assessment of both the comparative effects of TMF and TDF and the impact of switching from TDF to TMF, thereby reflecting real-world treatment scenarios. Virological, biochemical and imaging evaluations were performed throughout the study. RESULTS: At week 96, both groups achieved comparable virological suppression and maintained stable hepatic and renal function. However, total cholesterol and low-density lipoprotein cholesterol levels were significantly higher in the TMF group compared to the TDF group (P = 0.012 and P = 0.040, respectively). TDF was associated with a transient increase in serum phosphate (P = 0.030). After switching to TMF, lipid profiles in the former TDF group gradually aligned with those of the continuous TMF group by week 144, with no lipid abnormalities observed in either group. CONCLUSION: TMF provides sustained antiviral efficacy and maintains a favourable long-term lipid and renal safety profile. These findings support TMF as a viable first-line therapy and a switch option for CHB management in clinical practice.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Workflow of the clinical trial. TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate.
非 KM Figure
Figure 2Figure 2 Hepatitis B virus biomarkers dynamic changes between tenofovir amibufenamide group and tenofovir disoproxil fumarate group. A-E: The two groups showed consistent virological performance in terms of hepatitis B surface antigen (A), hepatitis B e antigen (B), hepatitis B virus (HBV)-DNA (C), HBV-RNA (D), HBV-microRNA-3 (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR: MicroRNA.
非 KM Figure
Figure 3Figure 3 Dynamic changes in lipid profiles between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B. A-E: The two groups exhibited comparable virological performance regarding cholesterol (A), low-density lipoprotein (B), high-density lipoprotein (C), triglycerides (D) and the triglycerides/high-density lipoprotein ratio (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; CHOL: Cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; TG: Triglycerides; TC: Total cholesterol.
非 KM Figure
Figure 4Figure 4 Dynamic changes in renal function between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B. A: Creatinine (Cr); B: Cr clearance rate; C: Phosphorus. TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; Cr: Creatinine; CLCR: Creatinine clearance rate; PHOS: Phosphorus.
非 KM Figure